Aurinia reports positive AURA –LV study outcome of voclosporin in treating lupus nephritis

Canadian-based clinical stage bio-pharmaceutical company Aurinia has reported positive results from its AURA –LV study of voclosporin in combination with mycophenolate mofetil against placebo to treat lupus nephritis (LN).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news